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  EVIDENCE-BASED ANSWER 
Routine liver function test monitoring is not required for all patients on isoniazid therapy for latent tuberculosis 
(TB) infection (strength of recommendation: B, based on case series). No clinical trials have studied the 
potential risks and benefits of routinely monitoring liver function tests for all patients taking isoniazid for latent 
TB infection. Data from 2 case series suggest that routine liver function test monitoring leads to withdrawal of 
isoniazid prophylaxis from about 6% of patients because of abnormal lab results.1,2 This is 10 to 60 times the 
hepatitis rate found in case series using a symptom-based monitoring strategy.3,6 Data are insufficient, 
however, to conclude that routine liver function test monitoring leads to a lower rate of fatal isoniazid hepatitis 
compared with a strategy of symptom-based screening. Given that complete recovery from nonfatal hepatitis is 
the rule, and that patients withdrawn from isoniazid prophylaxis remain at risk for developing active 
tuberculosis, current evidence does not support routine liver function test monitoring for all patients. 
  EVIDENCE SUMMARY 
Several large population-based case series have tried to define the incidence of isoniazid-induced hepatitis 
and fatal hepatitis. Because these series differed in patient selection, diagnostic criteria for hepatitis, and 
toxicity monitoring strategies, and because their data span decades, they provide limited insight. Data from 6 
large case series1,3-7 and 1 pooled compilation of published and unpublished reports8 are summarized in the 
Table. 
Two studies1,2 that defined hepatitis as asymptomatic liver function test elevation (>5 times normal) on monthly 
screening found a 6% to 6.4% incidence of hepatitis, a rate 10 to 60 times higher than 4 case series3-6 that 
relied on symptom-based monitoring. A pooled analysis of more than 200,000 patients receiving isoniazid 
prophylaxis and monitored according to 1983 American Thoracic Society guidelines reported an intermediate 
hepatitis rate (1.2%) and only 2 deaths.8 Mortality from isoniazid hepatitis is rare, whichever monitoring 
strategy is selected. Some deaths attributed to isoniazid prophylaxis may also have had other contributing 
causes, such as unrecognized hepatitis C; most cases and deaths reported in these large series occurred 
before testing for hepatitis C became available in 1991. 
Symptom-based monitoring strategies require stopping isoniazid promptly if symptoms of hepatotoxicity 
develop. In a series of 62 fatal cases of probable or possible isoniazid hepatitis, 42% had been monitored at 
least monthly for symptoms, and 38% stopped isoniazid within 1 week of symptom onset.9 Seven of the 8 
patients receiving a liver transplant following the development of fulminant, isoniazid-related hepatitis continued 
to take the drug for a least 10 days after onset of symptoms of hepatotoxicity.10 
Several series report increasing hepatitis risk with advancing age.1,3,5,6 In 1 series,3 rates were 3/1000 in those 
aged 20 to 34 years, 12/1000 in those aged 35 to 49 years, 23/1000 in those aged 50 to 64 years, and 8/1000 
after age 65. 
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INH hepatitis incidence and mortality rates: summary of the largest case 
series 
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a Withhold treatment in presence of active liver disease, limit prophylaxis of patients aged >35 to those at 
highest risk of developing active disease, baseline and periodic LFTs for those over 35, discontinue 
isoniazid if transaminases exceed 3 to 5 times normal. 
b Calculation based on life-table analysis, because of high dropout rate during treatment LFT, liver 
function test; AST, aspartate transaminase; ALT, alanine transaminase; IUSTCP, International Union 
Against Tuberculosis Committee on Prophylaxis 
  RECOMMENDATIONS FROM OTHERS 
The Centers for Disease Control and Prevention (CDC) and the American Thoracic Society joint guidelines for 
the treatment of latent TB infection state that baseline laboratory testing is not routinely indicated, even for 
persons aged >35 years, but may be considered for patients who are taking other hepatotoxic medications or 
have chronic medical conditions.11 
Baseline measurements of bilirubin and aspartate transaminase (AST) or alanine transaminase (ALT) along 
with monthly liver function test monitoring are recommended for patients with pre-existing liver disease, 
patients at risk for chronic liver disease, patients with HIV infection, pregnant or postpartum women, and 
regular users of alcohol. All patients should be evaluated at least monthly for symptoms of hepatitis, and liver 
function tests should also be obtained for patients with symptoms compatible with hepatotoxicity. The guideline 
suggests that isoniazid be stopped if liver function tests exceed 5 times the upper limits of normal, or 3 times 
the upper limits of normal if the patient is symptomatic. The Canadian Tuberculosis Standards (5th ed, 2000) 
recommend baseline AST before isoniazid preventive therapy is started, and regular monitoring in those with 
pre-existing liver disease, a history of ethanol abuse, or age ≥35 years.12 
CLINICAL COMMENTARY 
Patients need to understand risks and benefits of 
TB treatment 
 
Lauren  DeAlleaume,  MD 
University of Colorado Health Sciences Center,Denver 
As the number of immigrants increases, FPs will see more patients at high risk for TB. 
Patients whose risk of developing active TB exceeds the risk of isoniazid toxicity should 
be tested (targeted testing). It is challenging to ensure an asymptomatic patient completes 
a 9-month course of therapy while undergoing monthly monitoring for symptoms of 
isoniazid toxicity. Overall, only 60% of patients complete a full course of isoniazid. Clinical 
and public health systems that make it easier for patients to follow-up can enhance 
compliance. 
Patients need to understand the benefits of treatment and the symptoms of isoniazid 
toxicity. The CDC recommends clinical monitoring without routine blood testing for 
patients of any age without additional risk factors for isoniazid hepatitis. Excessive 
monitoring can lead to premature discontinuation of therapy because 10%–20% of 
patients develop some liver function test elevation. The CDC has an excellent course on 
the basics of latent TB testing and treatment ( at 
www.phppo.cdc.gov/phtn/tbmodules/Default.htm). Patient education materials and 
risk assessment and monitoring forms can be obtained from state health departments. 
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